MASTERINVEST Kapitalanlage GmbH Grows Position in Regeneron Pharmaceuticals, Inc. $REGN

MASTERINVEST Kapitalanlage GmbH increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 46.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,176 shares of the biopharmaceutical company’s stock after acquiring an additional 1,008 shares during the quarter. MASTERINVEST Kapitalanlage GmbH’s holdings in Regeneron Pharmaceuticals were worth $1,786,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors boosted its holdings in shares of Regeneron Pharmaceuticals by 7.2% during the 3rd quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 1,697 shares of the biopharmaceutical company’s stock valued at $954,000 after purchasing an additional 114 shares during the last quarter. Kesler Norman & Wride LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $249,000. Oregon Public Employees Retirement Fund lifted its position in shares of Regeneron Pharmaceuticals by 30.6% in the third quarter. Oregon Public Employees Retirement Fund now owns 11,667 shares of the biopharmaceutical company’s stock worth $6,560,000 after buying an additional 2,736 shares in the last quarter. Cromwell Holdings LLC lifted its position in shares of Regeneron Pharmaceuticals by 238.6% in the third quarter. Cromwell Holdings LLC now owns 342 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 241 shares in the last quarter. Finally, Capital Investment Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 15.2% during the third quarter. Capital Investment Advisors LLC now owns 477 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 63 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.6%

Shares of REGN opened at $796.55 on Friday. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $738.12 and a 200 day moving average of $628.80. The company has a market cap of $83.72 billion, a PE ratio of 19.07, a P/E/G ratio of 2.16 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $12.46 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 8,431 shares of company stock valued at $5,733,521 over the last 90 days. Insiders own 7.02% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Canaccord Genuity Group boosted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, UBS Group lifted their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $791.05.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.